

Resource Summary Report

Generated by NIF on Jul 31, 2026

Brilliant Violet 421(TM) anti-mouse CD80

RRID:AB_10900989

Type: Antibody

Proper Citation

BioLegend Cat# 104725, RRID:AB_10900989

Antibody Information

URL: http://antibodyregistry.org/AB_10900989

Proper Citation: BioLegend Cat# 104725, RRID:AB_10900989

Target Antigen: CD80

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: FC, IHC-F

Antibody Name: Brilliant Violet 421(TM) anti-mouse CD80

Description: This monoclonal targets CD80

Target Organism: mouse

Clone ID: Clone 16-10A1

Antibody ID: AB_10900989

Vendor: BioLegend

Catalog Number: 104725

Alternative Catalog Numbers: 104726

Record Creation Time: 20250819T233721+0000

Record Last Update: 20250820T055424+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-mouse CD80.

No alerts have been found for Brilliant Violet 421(TM) anti-mouse CD80.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Zuo Y, et al. (2025) Monocyte-derived cells promote transient insult-induced brain injury by enhancing CD8+ T cell response. Cell reports, 44(11), 116528.

Hao Y, et al. (2025) Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition. Cancer immunology research, 13(2), 185.

He X, et al. (2025) Lysine vitcylation is a vitamin C-derived protein modification that enhances STAT1-mediated immune response. Cell, 188(7), 1858.

Broderick C, et al. (2025) A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma. Cancer discovery, 15(8), 1717.

Xu J, et al. (2024) PNMA2 forms immunogenic non-enveloped virus-like capsids associated with paraneoplastic neurological syndrome. Cell, 187(4), 831.

Barisic D, et al. (2024) ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. Cancer cell.

Tian T, et al. (2023) FBXO38 mediates FGL1 ubiquitination and degradation to enhance cancer immunity and suppress inflammation. Cell reports, 42(11), 113362.

Heinlein M, et al. (2022) The acetyltransferase KAT7 is required for thymic epithelial cell expansion, expression of AIRE target genes, and thymic tolerance. Science immunology, 7(67), eabb6032.

Kumagai S, et al. (2022) Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer cell, 40(2), 201.

Vergani S, et al. (2022) A self-sustaining layer of early-life-origin B cells drives steady-state IgA responses in the adult gut. Immunity, 55(10), 1829.

Mirshahi F, et al. (2022) Distinct hepatic immunological patterns are associated with the progression or inhibition of hepatocellular carcinoma. *Cell reports*, 38(9), 110454.

Duraiswamy J, et al. (2021) Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. *Cancer cell*, 39(12), 1623.

Venturutti L, et al. (2020) TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. *Cell*, 182(2), 297.

McNamara HA, et al. (2020) Antibody Feedback Limits the Expansion of B Cell Responses to Malaria Vaccination but Drives Diversification of the Humoral Response. *Cell host & microbe*, 28(4), 572.

Kumagai S, et al. (2020) An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells. *Immunity*, 53(1), 187.